Enfortumab vedotin
Showing 1 - 25 of 275
Pancreatic Ductal Adenocarcinoma, Pancreas Adenocarcinoma, Pancreas Cancer Trial in Kansas City (Enfortumab vedotin)
Recruiting
- Pancreatic Ductal Adenocarcinoma
- +2 more
- Enfortumab vedotin
-
Kansas City, KansasUniversity of Kansas Cancer Center
Jun 23, 2023
Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma Trial in Philadelphia (Enfortumab
Not yet recruiting
- Urothelial Carcinoma
- +2 more
- Enfortumab vedotin
- Pembrolizumab
-
Philadelphia, PennsylvaniaFox Chase Cancer Center - Philadelphia
Jun 27, 2023
Metastatic Penile Squamous Cell Carcinoma, Stage III Penile Cancer AJCC v8, Stage IV Penile Cancer AJCC v8 Trial in Phoenix,
Not yet recruiting
- Metastatic Penile Squamous Cell Carcinoma
- +3 more
- Enfortumab Vedotin
-
Phoenix, Arizona
- +2 more
Oct 23, 2023
Adenocarcinoma of the Bladder, Squamous Cell Carcinoma of the Bladder, Testicular Germ Cell Tumors Trial run by the National
Not yet recruiting
- Adenocarcinoma of the Bladder
- +2 more
- Enfortumab vedotin
- Pembrolizumab
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Sep 22, 2023
Metastatic Castration-resistant Prostate Cancer Trial in Salt Lake City (Enfortumab vedotin)
Recruiting
- Metastatic Castration-resistant Prostate Cancer
- Enfortumab vedotin
-
Salt Lake City, UtahHuntsman Cancer Institute
Jan 24, 2023
Renal Pelvis and Ureter Urothelial Carcinoma Trial in Los Angeles (procedure, drug, biological)
Not yet recruiting
- Renal Pelvis and Ureter Urothelial Carcinoma
- Biopsy
- +5 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Mar 15, 2023
Adults in South Korea With Cancer Who Receive PADCEV Injection
Recruiting
- Urothelial Cancer
- Enfortumab Vedotin
-
Seoul, Korea, Republic ofKR82004
Aug 22, 2023
Urothelial Carcinoma Trial in United States (Enfortumab Vedotin, Radical surgery)
Not yet recruiting
- Urothelial Carcinoma
- Enfortumab Vedotin
- Radical surgery
-
Basking Ridge, New Jersey
- +6 more
May 11, 2023
Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma, Metastatic
Recruiting
- Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation
- +3 more
- Cabozantinib S-malate
- +3 more
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Aug 8, 2022
Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Tumor Trial in Atlanta (procedure,
Not yet recruiting
- Bladder Squamous Cell Carcinoma
- +10 more
- Biospecimen Collection
- +5 more
-
Atlanta, Georgia
- +3 more
Feb 20, 2023
Urothelial Cancer, Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter Trial in
Recruiting
- Urothelial Cancer
- +3 more
- Sacituzumab Govitecan (SG)
- Enfortumab vedotin-ejfv (EV)
-
Boston, MassachusettsDana Farber Cancer Institute
Sep 28, 2022
High Grade Urothelial Carcinoma, Bladder Cancer, Urothelial Carcinoma Bladder Trial in Washington, Baltimore (Enfortumab
Not yet recruiting
- High Grade Urothelial Carcinoma
- +2 more
- Enfortumab vedotin
- Pembrolizumab
-
Washington, District of Columbia
- +1 more
Jan 5, 2023
Metastatic Urothelial Carcinoma, Urothelial Tumors Trial (Coformulated favezelimab/pembrolizumab, Coformulated
Not yet recruiting
- Metastatic Urothelial Carcinoma
- Urothelial Neoplasms
- Coformulated favezelimab/pembrolizumab
- +3 more
- (no location specified)
Apr 26, 2023
Metastatic Urothelial Cancer Trial in China (Enfortumab vedotin)
Active, not recruiting
- Metastatic Urothelial Cancer
- Enfortumab vedotin
-
Beijing, China
- +7 more
Aug 23, 2022
Urothelial Carcinoma Trial in United States (Enfortumab vedotin, Pembrolizumab)
Recruiting
- Urothelial Carcinoma
- Enfortumab vedotin
- Pembrolizumab
-
Basking Ridge, New Jersey
- +6 more
Jun 6, 2022
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter
Recruiting
- Locally Advanced Bladder Urothelial Carcinoma
- +18 more
- Enfortumab Vedotin
- Erdafitinib
-
Los Angeles, California
- +2 more
Jun 28, 2022
Cancer, Advanced Solid Tumor Trial in Kettering (lorlatinib, encorafenib + binimetinib, talazoparib)
Recruiting
- Cancer
- Advanced Solid Tumor
- lorlatinib
- +4 more
-
Kettering, OhioKettering Health Network
Oct 14, 2022
Advanced or Metastatic Solid Malignancies Trial in United States (Sitravatinib, Nivolumab, Pembrolizumab)
Enrolling by invitation
- Advanced or Metastatic Solid Malignancies
- Sitravatinib
- +4 more
-
Beverly Hills, California
- +12 more
Aug 23, 2022
Carcinoma, Transitional Cell, Urinary Bladder Tumors, Urologic Tumors Trial in Worldwide (enfortumab vedotin (EV),
Active, not recruiting
- Carcinoma, Transitional Cell
- +6 more
- enfortumab vedotin (EV)
- +4 more
-
Anchorage, Alaska
- +105 more
Dec 19, 2022
Metastatic Urothelial Cancer Trial in Japan (Enfortumab vedotin)
Completed
- Metastatic Urothelial Cancer
- Enfortumab vedotin
-
Tsukuba, Ibaraki, Japan
- +7 more
Mar 2, 2020
Muscle Invasive Bladder Cancer Trial in Worldwide (biological, procedure, drug)
Recruiting
- Muscle Invasive Bladder Cancer
- Pembrolizumab
- +4 more
-
Phoenix, Arizona
- +136 more
Aug 5, 2022
Reporting of Antibody-Drug Conjugate Associated Sepsis-related
Completed
- Sepsis (SMQ)
- +2 more
- Antibody-Drug Conjugate
- Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate
-
Changsha, Hunan, ChinaCentral South University
Jun 19, 2022
Locally Advanced or Metastatic Urothelial Carcinoma (UC) Trial in United States (enfortumab vedotin (EV))
Approved for marketing
- Locally Advanced or Metastatic Urothelial Carcinoma (UC)
- enfortumab vedotin (EV)
-
Los Angeles, California
- +14 more
Jan 9, 2020
Cisplatin-Ineligible Metastatic Bladder Cancer and The Role of
Not yet recruiting
- Bladder Cancer
- +3 more
- Geriatric-8 Survey
- +2 more
-
Boston, Massachusetts
- +1 more
Nov 14, 2023